Response-guided neoadjuvant chemotherapy for breast cancer.

  title={Response-guided neoadjuvant chemotherapy for breast cancer.},
  author={Gunter von Minckwitz and Jens Uwe Blohmer and Serban Dan Costa and Carsten Denkert and Holger Eidtmann and Wolfgang Eiermann and Bernd Gerber and Claus Hanusch and Joern Hilfrich and Jens B. Huober and Christian Jackisch and Manfred Kaufmann and Sherko K{\"u}mmel and Stefan Paepke and Andreas Schneeweiss and Michael Untch and Dirk Michael Zahm and Keyur Mehta and Sibylle Loibl},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={31 29},
PURPOSE We investigated disease-free survival (DFS) and overall survival (OS) after response-guided neoadjuvant chemotherapy in patients with early breast cancer. PATIENTS AND METHODS We treated 2,072 patients with two cycles of docetaxel, doxorubicin, and cyclophosphamide (TAC) and randomly assigned early responders to four (n = 704) or six (n = 686) additional TAC cycles, and early nonresponders to four cycles of TAC (n = 321) or vinorelbine and capecitabine (NX; n = 301) before surgery… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 20 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 84 extracted citations


Publications referenced by this paper.
Showing 1-10 of 24 references

Zoledronic acid (ZOL) as add on therapy in patients with tumor residuals after neoadjuvant chemotherapy for primary breast cancer: First interim safety analysis of the NATAN study (GBG 36)

  • G von Minckwitz, MD Zahm, H Eidtmann
  • Presented at the American Society of Clinical…
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…